On Demand Webinar
How to Build an AAV Platform that Produces Higher Titers & Percent Full Capsids
Learn the best practices for improving transfection yield across serotypes, media, and cell types from scientists at Mirus Bio and ReciBioPharm
Free Viewing
How to Build an AAV Platform that Produces Higher Titers & Percent Full Capsids
Learn the best practices for improving transfection yield across serotypes, media, and cell types from scientists at Mirus Bio and ReciBioPharm
What you’ll find inside:
- How upstream processes achieve 2-10X higher titers and percent full capsids with TransIT-VirusGEN® and RevIT™ AAV Enhancer
- What transfection efficiency results you can expect across multiple serotypes, media, and suspension cell types
- How to scale from R&D to GMP
- How smart manufacturing processes enable affordability to drug developers and greater access to therapeutics for patients
- How upstream can handoff to downstream with higher quality
- How to cut costs on plasmid DNA
- How to compare transfection reagents
There is an increasing need for more effective, scalable, and cost-conscious manufacturing of recombinant AAV and LVV
Selecting the appropriate transfection reagent is paramount for successful viral research, as it directly impacts the efficiency and effectiveness of gene delivery. Additionally, boosting the transfection process with enhancers like Mirus Bio’s RevIT AAV Enhancer can further enhance viral production by increasing titer and percent full capsids, crucial for optimizing your upstream processes.
The Mirus Bio FAS team offers invaluable expertise and guidance, to assist your selection of the most suitable transfection reagents and enhancers and to optimize protocols for your specific virus productionneeds. Their assistance not only expedites your testing but also ensures reliable and reproducible results, empowering you to focus on your core objectives.
“We chose to transfect with TransIT-VirusGEN and RevIT based on the success we saw and in an attempt to maximize production.
The thought here was that with higher yields we would be able to produce a large number of doses per 50 liter bioreactor, therefore reducing the cost per dose.”
“We chose to transfect with TransIT-VirusGEN and RevIT based on the success we saw and in an attempt to maximize production.
The thought here was that with higher yields we would be able to produce a large number of doses per 50 liter bioreactor, therefore reducing the cost per dose.”
Chris Brown
Senior Scientist of Process Development
ReciBioPharm
